361 related articles for article (PubMed ID: 32668113)
1. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H;
N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113
[TBL] [Abstract][Full Text] [Related]
2. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Lebwohl MG; Kircik LH; Moore AY; Stein Gold L; Draelos ZD; Gooderham MJ; Papp KA; Bagel J; Bhatia N; Del Rosso JQ; Ferris LK; Green LJ; Hebert AA; Jones T; Kempers SE; Pariser DM; Yamauchi PS; Zirwas M; Albrecht L; Devani AR; Lomaga M; Feng A; Snyder S; Burnett P; Higham RC; Berk DR
JAMA; 2022 Sep; 328(11):1073-1084. PubMed ID: 36125472
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
[TBL] [Abstract][Full Text] [Related]
4. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test.
Snape SD; Wigger-Alberti W; Goehring UM
Br J Dermatol; 2016 Sep; 175(3):479-86. PubMed ID: 27038440
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis.
Smith B; Collier MR; Wu JJ
JAMA; 2023 Feb; 329(7):594-595. PubMed ID: 36809326
[No Abstract] [Full Text] [Related]
6. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis-Reply.
Lebwohl MG; Hebert AA; Gooderham MJ
JAMA; 2023 Feb; 329(7):595. PubMed ID: 36809324
[No Abstract] [Full Text] [Related]
7. Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
Stein Gold L; Alonso-Llamazares J; Draelos ZD; Gooderham MJ; Kempers SE; Kircik LH; Lebwohl MG; Papp KA; Pariser DM; Toth DP; Yosipovitch G; Higham RC; Feng A; Berk DR
Am J Clin Dermatol; 2023 Mar; 24(2):305-313. PubMed ID: 36370336
[TBL] [Abstract][Full Text] [Related]
8. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Lebwohl MG; Stein Gold L; Strober B; Papp KA; Armstrong AW; Bagel J; Kircik L; Ehst B; Hong HC; Soung J; Fromowitz J; Guenthner S; Piscitelli SC; Rubenstein DS; Brown PM; Tallman AM; Bissonnette R
N Engl J Med; 2021 Dec; 385(24):2219-2229. PubMed ID: 34879448
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis.
Nicolas SE; Bear MD; Kanaan AO; Coman OA; Dima L
Am J Ther; 2023 Nov-Dec 01; 30(6):e535-e542. PubMed ID: 37921681
[TBL] [Abstract][Full Text] [Related]
10. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis - results from a randomized controlled trial (PSORRO).
Gyldenløve M; Sørensen JA; Fage S; Meteran H; Skov L; Zachariae C; Knop FK; Nielsen ML; Egeberg A
J Am Acad Dermatol; 2024 Jul; 91(1):64-71. PubMed ID: 38431099
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Zirwas MJ; Draelos ZD; DuBois J; Kircik LH; Moore AY; Stein Gold L; Alonso-Llamazares J; Bukhalo M; Bruce S; Eads K; Green LJ; Guenthner ST; Ferris LK; Forman SB; Kempers SE; Lain E; Lynde CW; Pariser DM; Toth DP; Yamauchi PS; Higham RC; Krupa D; Burnett P; Berk DR
JAMA Dermatol; 2023 Jun; 159(6):613-620. PubMed ID: 37133856
[TBL] [Abstract][Full Text] [Related]
12. A Review of Topical Roflumilast for the Treatment of Plaque Psoriasis.
Pixley JN; Schaetzle T; Feldman SR
Ann Pharmacother; 2023 Aug; 57(8):966-969. PubMed ID: 36420929
[TBL] [Abstract][Full Text] [Related]
13. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
15. Topical Roflumilast for Plaque Psoriasis.
O'Toole A; Gooderham M
Skin Therapy Lett; 2023 Sep; 28(5):1-4. PubMed ID: 37734074
[TBL] [Abstract][Full Text] [Related]
16. ZORYVE
Gupta AK; Ravi SP; Vincent K; Abramovits W
Skinmed; 2023; 21(5):357-359. PubMed ID: 37945365
[TBL] [Abstract][Full Text] [Related]
17. Topical roflumilast for the treatment of psoriasis.
Drakos A; Vender R; Torres T
Expert Rev Clin Immunol; 2023; 19(9):1053-1062. PubMed ID: 37243575
[TBL] [Abstract][Full Text] [Related]
18. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
19. Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Blauvelt A; Draelos ZD; Stein Gold L; Alonso-Llamazares J; Bhatia N; DuBois J; Forman SB; Gooderham M; Green L; Guenthner ST; Hebert AA; Lain E; Moore AY; Papp KA; Zirwas M; Kato S; Snyder S; Krupa D; Burnett P; Berk DR; Chu DH
J Am Acad Dermatol; 2024 May; 90(5):986-993. PubMed ID: 38253129
[TBL] [Abstract][Full Text] [Related]
20. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
